When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy.
CONCLUSIONS: PI-RADSv2 category 3 lesions are often not CSPCa. PSAD predicted CSPCa in men with a prior negative biopsy; however, PSAD alone had limited value, and accuracy improved when using a model incorporating PSAD with clinical stage and MR lesion size.
PMID: 33007183 [PubMed - as supplied by publisher]
Source: Canadian Urological Association Journal - Category: Urology & Nephrology Authors: Lim C, Abreu-Gomez J, Leblond MA, Carrion I, Vesprini D, Schieda N, Klotz L Tags: Can Urol Assoc J Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | MRI Scan | Pathology | Prostate Cancer | Study | Ultrasound | Urology & Nephrology